Sulfamide
(Synonyms: Sulfuric diamide) 目录号 : GC25973Sulfamide (Sulfuric diamide) is used in organic chemistry for synthesis.
Cas No.:7803-58-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Sulfamide (Sulfuric diamide) is used in organic chemistry for synthesis.
| Cas No. | 7803-58-9 | SDF | Download SDF |
| 别名 | Sulfuric diamide | ||
| 分子式 | H4N2O2S | 分子量 | 96.11 |
| 溶解度 | DMSO: 100 mg/mL (1040.47 mM);; | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 10.4047 mL | 52.0237 mL | 104.0474 mL |
| 5 mM | 2.0809 mL | 10.4047 mL | 20.8095 mL |
| 10 mM | 1.0405 mL | 5.2024 mL | 10.4047 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
The role of Sulfamide derivatives in medicinal chemistry: a patent review (2006-2008)
Expert Opin Ther Pat 2009 Oct;19(10):1449-53.PMID:19650745DOI:10.1517/13543770903185920.
Background: The Sulfamide (R(2)NSO(2)NR(2)) functionality is an acceptable functional group in medicinal chemistry when incorporated into putative small-molecule therapeutics, as it has the potential to form several electrostatic interactions with protein and other targets. The clinically-useful broad spectrum antibiotic doripenem contains a mono-substituted Sulfamide. The Sulfamide functional group is often found to substitute for sulfonamide, sulfamate or urea functionality. Objective/method: During the period of 2006-2008, there were nine published patents in which all or most reported compounds contained the Sulfamide functional group. There are also patents in which the structures disclosed contain a cyclic Sulfamide functional group. Further, there are patents published during this timeframe that contain only a few sulfamide-containing examples, typically as a bioisosteric replacement for a sulfonamide moiety. In this review, we focus on those published patents in which most compounds disclosed are sulfamides and only briefly highlight examples in which sulfamides are included among a large list of other suitable functionalities. Conclusion: While the Sulfamide functionality is still fairly under-represented in medicinal chemistry, it is a valuable and versatile group that will gain increasing acceptance and favor in the future.
Sulfamide: A Promising Deep-Ultraviolet Nonlinear Optical Crystal Assembled from Polar Covalent [SO2 (NH2 )2 ] Tetrahedra
Angew Chem Int Ed Engl 2022 Apr 19;61(17):e202200395.PMID:35179290DOI:10.1002/anie.202200395.
For the first time, the polar covalent tetrahedron [SO2 (NH2 )2 ] is revealed as a new deep-ultraviolet (DUV) nonlinear optical (NLO)-active unit according to theoretical calculations. Furthermore, Sulfamide consisting of polar [SO2 (NH2 )2 ] units was confirmed as an excellent candidate as a DUV NLO crystal. Sulfamide provides the optimal balance between composition, structure, and properties, in addition to a very short absorption of 160 nm. It achieves multiple optical performance records for non-π-conjugated DUV NLO materials, including the strongest second harmonic generation (SHG) efficiency (about 4 times that of KDP), the largest birefringence (obv.: 0.07@589.3 nm) and the shortest SHG wavelength predicted as 188 nm.
Amide-sulfamide modulators as effective anti-tumor metastatic agents targeting CXCR4/CXCL12 axis
Eur J Med Chem 2020 Jan 1;185:111823.PMID:31698158DOI:10.1016/j.ejmech.2019.111823.
Breast cancer is the most frequently diagnosed malignancy and the second common cause of death in women worldwide. High mortality in breast cancer is frequently associated with metastatic progression rather than the primary tumor itself. It has been recently identified that the CXCR4/CXCL12 axis plays a pivotal role in breast cancer metastasis, especially in directing metastatic cancer cells to CXCL12-riched organs and tissues. Herein, taking the amide-sulfamide as the lead structure, the second-round structural modifications to the Sulfamide structure were performed to obtain more active CXCR4 modulators against tumor metastasis. Both in vivo and in vitro experiments illustrated that compound IIIe possessed potent CXCR4 binding affinity, excellent anti-metastatic and anti-angiogenetic activity against breast cancer. More importantly, in a mouse breast cancer lung metastasis model, compound IIIe exerted a significant inhibitory effect on breast cancer metastasis. Taken together, all these positive results demonstrated that developing of CXCR4 modulators is a promising strategy to mediate breast cancer metastasis.
Sulfamide derivatives with selective carbonic anhydrase VII inhibitory action
Bioorg Med Chem 2016 Feb 15;24(4):894-901.PMID:26795114DOI:10.1016/j.bmc.2016.01.012.
A set of N,N'-disubstituted sulfamides and sodium cyclamate have been tested for their inhibitory action against six isoforms of carbonic anhydrase (CA, EC 4.2.1.1) found in the brain, that is, CA I, CA II, CA VII, CA IX, CA XII and CA XIV, some of which are involved in epileptogenesis. The biological data showed interesting results for CA VII inhibition, the isozyme thought to be a novel antiepileptic target. Strong CA VII inhibitors, with Ki values in the low nanomolar-subnanomolar range were identified. Some of these derivatives showed selectivity for inhibition of CA VII versus the ubiquitous isoform CA II, for which the Ki values were in the micromolar range. Molecular modeling approaches were employed to understand the binding interactions between these compounds and the two CA isoforms, since the mechanism of action of such disubstituted sulfamides was not yet investigated by means of X-ray crystallography.
Tuning the Anomeric Effect in Sulfamide with Superacids
Chemistry 2018 Oct 22;24(59):15825-15830.PMID:30198170DOI:10.1002/chem.201804009.
This study shows that the anomeric effect (negative hyperconjugation) that arises in Sulfamide, as a result of the relatively short S-N bonds, can be tuned by the utilization of superacidic media. Sulfamide was reacted in binary superacidic systems XF/MF5 (M=As, Sb; X=H, D) and HF/BF3 . The colorless salts formed, [X2 NSO2 NX3 ]+ [MF6 ]- and [H2 NSO2 NH3 ]+ [BF4 ]- were characterized by low-temperature vibrational spectroscopy. In the case of [H2 NSO2 NH3 ]+ [BF4 ]- , a single crystal X-ray diffraction study was performed. The salt crystallizes in the monoclinic space group P21 /c with four formula units per unit cell. An exclusive N,N'-diprotonation was observed in the superacidic system HF/SbF5 when using several equivalents of the Lewis acid. Low-temperature vibrational spectra as well as a single-crystal X-ray structure of [H3 NSO2 NH3 ]2+ 2 [SbF6 ]- ⋅2 HF are reported. The salt crystallizes in the orthorhombic space group Pna21 with four formula units per unit cell. Upon mono- or diprotonation of Sulfamide, remarkable structural changes of the sulfur-nitrogen bond lengths were observed. Herein, these changes are discussed together with quantum chemical calculations.